SELECTA BIOSCIENCES
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.
SELECTA BIOSCIENCES
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2008-01-01
Address:
Watertown, Massachusetts, United States
Country:
United States
Website Url:
http://www.selectabio.com
Total Employee:
51+
Status:
Active
Contact:
(617) 923-1400
Total Funding:
320.29 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon WordPress Domain Not Resolving Wordpress Plugins Nginx
Current Advisors List
Board_member
2008-01-01
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
David Abraham General Counsel and Corporate Secretary @ Selecta Biosciences
General Counsel and Corporate Secretary
Kevin Tan CFO @ Selecta Biosciences
CFO
2021-01-01
Lloyd Johnston Chief Operating Officer and Senior Vice President R&D @ Selecta Biosciences
Chief Operating Officer and Senior Vice President R&D
2014-01-01
Takashi Kei Kishimoto Chief Scientific Officer @ Selecta Biosciences
Chief Scientific Officer
Wes DeHaan Vice President Program Management @ Selecta Biosciences
Vice President Program Management
2017-01-01
Nishan de Silva Director @ Selecta Biosciences
Director
2021-06-01
Peter Keller Chief Business Officer @ Selecta Biosciences
Chief Business Officer
Peter G. Traber Chief Medical Officer @ Selecta Biosciences
Chief Medical Officer
2020-08-01
Omid Farokhzad Founder, Board of Directors and Vice Chairman on the Board @ Selecta Biosciences
Founder, Board of Directors and Vice Chairman on the Board
2008-01-01
Founder
Stock Details
Investors List
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Selecta Biosciences
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Selecta Biosciences
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Post-IPO Equity - Selecta Biosciences
Polaris Partners
Polaris Partners investment in Series E - Selecta Biosciences
Sanofi Ventures
Sanofi Ventures investment in Series E - Selecta Biosciences
Sphera Funds Management
Sphera Funds Management investment in Series E - Selecta Biosciences
Eminent Venture Capital
Eminent Venture Capital investment in Series E - Selecta Biosciences
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series E - Selecta Biosciences
Leukon Investments
Leukon Investments investment in Series E - Selecta Biosciences
I2BF Global Ventures
I2BF Global Ventures investment in Series E - Selecta Biosciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-12-06 | Cyrus Biotechnology | Selecta Biosciences investment in Series B - Cyrus Biotechnology | 18 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-20 | Selecta Biosciences Announces Appointment of Kevin Tan as Chief Financial Officer |
Official Site Inspections
http://www.selectabio.com Semrush global rank: 4.76 M Semrush visits lastest month: 1.95 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Selecta Biosciences"
Home - Cartesian
Pioneering mRNA Cell Therapy for autoimmune diseases Pioneering RNA Cell Therapy for autoimmune diseases UNDERSTAND OUR SCIENCE Our Commitment to our Patients We …See details»
Selecta Biosciences - Crunchbase Company Profile & Funding
Contact Email info@selectabio.com Phone Number (617) 923-1400 Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory …See details»
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Nov 13, 2023 – Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline …See details»
Selecta Biosciences - LinkedIn
Selecta Biosciences | 3,627 followers on LinkedIn. Pioneering RNA cell therapy for autoimmune disease | In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with …See details»
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Nov 13, 2023 Selecta Biosciences, Inc. – Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease –See details»
Selecta Biosciences - PitchBook
Selecta Biosciences General Information Description. Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance …See details»
Selecta Announces Transition of Manufacturing and Clinical …
WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ …See details»
Selecta Biosciences, Inc. | LinkedIn
Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform.See details»
Investor Overview - Cartesian Therapeutics, Inc
Nov 7, 2024 Cartesian Therapeutics is a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases. Leveraging its proprietary …See details»
Selecta Biosciences and Cartesian Therapeutics Merge - citybiz
Nov 13, 2023 WATERTOWN, Mass. and GAITHERSBURG, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that it has …See details»
Selecta Biosciences Appoints Peter G. Traber, MD as Chief
Aug 3, 2020 “I am proud to be part of an organization that is pioneering innovations that may advance the treatment of a number of challenging diseases with unmet needs,” said Dr. …See details»
Selecta Announces Transition of Manufacturing and Clinical …
WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated …See details»
Selecta Biosciences and Cartesian Therapeutics Announce
Nov 13, 2023 In connection with the transactions, a transferrable contingent value right (a “CVR”) will be distributed to Selecta stockholders and holders of Selecta’s warrants issued in …See details»
Selecta Biosciences Announces Appointment of Blaine Davis as …
WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ …See details»
Selecta Announces Transition of Manufacturing and Clinical
WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated...See details»
Selecta Biosciences and Sobi Announce Completion of
Dec 1, 2021 For more information, please visit www.selectabio.com. Sobi Sobi is a specialized international biopharmaceutical company transforming the lives of people with rare diseases. …See details»
Selecta Biosciences Announces Merger with Cartesian
Nov 13, 2023 Management and Organization. The combined company will be led by Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., and current Chief Financial Officer, Blaine …See details»
Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s ...
Aug 7, 2019 Selecta’s proprietary gene therapy product candidates are in preclinical development for certain rare inborn errors of metabolism and incorporate ImmTOR with the …See details»
Selecta Biosciences Announces Strategic Licensing Agreement
Oct 4, 2021 --Selecta Biosciences, Inc., a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate …See details»
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Nov 13, 2023 Management and Organization. The combined company will be led by Selecta’s Chief Executive Officer, Carsten Brunn, ... For more information, please visit …See details»